Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) in a report released on Thursday. The firm set an “overweight” rating on the stock.
Other research analysts also recently issued reports about the stock. HC Wainwright upgraded shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Monday, October 13th. Wall Street Zen upgraded Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. Piper Sandler restated an “overweight” rating and set a $12.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Royal Bank Of Canada reduced their price objective on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 4th. Finally, Robert W. Baird decreased their price target on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 9th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.
Check Out Our Latest Stock Analysis on KPTI
Karyopharm Therapeutics Trading Down 3.8%
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.52). The business had revenue of $44.04 million during the quarter, compared to analysts’ expectations of $39.56 million. As a group, analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.
Institutional Trading of Karyopharm Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in KPTI. ADAR1 Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics in the 3rd quarter valued at about $164,000. Bridgeway Capital Management LLC bought a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $163,000. Bank of America Corp DE raised its stake in Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $56,000. Finally, Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $45,000. 66.44% of the stock is owned by institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.
Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.
Featured Stories
- Five stocks we like better than Karyopharm Therapeutics
- The day the gold market broke
- Buy this Gold Stock Before May 2026
- Trump Planning to Use Public Law 63-43: Prepare Now
- Forget AI, This Will Be the Next Big Tech Breakthrough
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
